Processa Pharmaceuticals (PCSA) Insider Yorke Sells 203 Shares
Justin Yorke sold 203 shares of Processa Pharmaceuticals on June 26, 2026, adding to a flurry of recent insider moves at the biotech firm.
Reviewed by automated data checks against the source filing. How we make and check alerts
Justin Yorke sold 203 shares of Processa Pharmaceuticals, Inc. ($PCSA) on June 26, 2026. The trade was reported to the SEC in a Form 4 filing.
Since the trade, $PCSA is up 12.9% after 1 week, up 39.2% after 1 month and down 9.1% to date (from the $1.86 close on Jun 26, 2026).
PCSA
Processa Pharmaceuticals, Inc.
Key Points
- Justin Yorke disposed of 203 shares of Processa Pharmaceuticals, Inc. (NasdaqCM: PCSA) on June 26, 2026.
- The transaction took place as shares traded near $1.92, well below their 52-week high of $14.25.
- Several other insiders, including Khoso Baluch and James Neal, also executed transactions on June 26, 2026.
Get $PCSA trade alerts by text
We text you when insiders, Congress or big funds trade $PCSA. Free.
Not investment advice. EarningsIQ is not a registered investment adviser, and this automated Processa Pharmaceuticals, Inc. alert may contain errors. Disclosures
Justin Yorke Executes Insider Trade at Processa Pharmaceuticals
On June 26, 2026, Justin Yorke carried out a transaction involving Processa Pharmaceuticals, Inc. (NasdaqCM: PCSA), disposing of 203 shares. The filing provides a window into recent insider adjustments at the clinical-stage biotech firm, coming at a time when shares change hands in the lower part of their historical trading range.
Recent Insider Transactions at the Firm
The transaction coincides with a cluster of other insider updates reported on June 26, 2026. On that same day, Khoso Baluch acquired 203 shares, and James Neal also picked up 203 shares. These moves follow an earlier purchase on June 15, 2026, when Patrick Lin, who serves as Chief Business and Strategy Officer, bought 1,831 shares at an average price of $2.22 per share for a total value of $4,064.82.
Stock Performance and Valuation Context
Processa Pharmaceuticals shares traded recently at $1.92. The stock has experienced a wide trading span over the past year, reaching a 52-week low of $1.67 and a 52-week high of $14.25. Its 50-day moving average stands at $2.21, while the 200-day moving average sits at $2.76. The company carries a market capitalization of roughly $5.14 million.
Clinical Pipeline and Corporate Focus
Processa Pharmaceuticals works on developing cancer treatments and non-oncology drugs designed to improve patient safety and therapy efficacy. Its oncology pipeline features candidates like NGC-Cap for solid tumors and NGC-Iri for lung and other cancers. Non-oncology projects include treatments for glomerular diseases and gastroparesis disorders. Based in Vero Beach, Florida, the firm continues to advance its clinical trials while managing its operational footprint with a lean team of 12 employees.
What to Watch at Processa Pharmaceuticals, Inc.
Market participants tracking Processa Pharmaceuticals will likely monitor future Form 4 filings for further updates on executive and director ownership shifts. Additional attention will turn toward corporate progress reports regarding the firm's ongoing clinical trials and upcoming financial disclosures.
Related Filing Alerts
Source: Justin Yorke's Form 4 filing on $PCSA (Jun 26, 2026). Find the original filing: PCSA Form 4 filings on SEC EDGAR. Written by software, not financial advice. How we make alerts